Deaths from endometrial cancer (EC) are rising in the United States, with the highest mortality rates reported for Black patients. Weigelt, Marra, and colleagues evaluated 1,882 ECs subjected to clinical tumor–normal panel sequencing, and found high-risk histologic types, including serous carcinoma and carcinosarcoma, and ECs of the poor outcome–related copy number–high/TP53 abnormal molecular subtype to be more prevalent in self-identified Black patients/patients of African genetic ancestry. Lower rates of actionable alterations that confer benefit from immunotherapy were observed in ECs from Black compared to White patients. Together, these findings on the molecular features underpinning EC disparities emphasize the importance of increasing research and clinical trials in high-risk ECs.

See article, p. 2356.

Effective therapies are lacking for patients with H3K27M-mutant diffuse midline glioma (DMG). Venneti, Kawakibi, Ji, Waszak, Sweha, Mota, Pun, and colleagues reported on the clinical results of ONC201 in patients with H3K27M-DMG from two completed clinical...

You do not currently have access to this content.